. Author manuscript; available in PMC: 2023 Aug 1.

Published in final edited form as: Expert Opin Biol Ther. 2021 May 9;22(8):1017–1027. doi: 10.1080/14712598.2021.1922665

Table 3:

HER2 BsAb’s in clinical development. The details of Table 3 are derived from http://clinicaltrials.gov/.

Agent	Listings	N	Phase	Target
ZW25 (Zymeworks)	NCT04276493 NCT02892123	50 234	Ib/2	2 distinct sites on HER2
ZW49 (Zymeworks)	NCT03821233	174	1	2 sites on HER2 (plus ADC delivery)
KN026 (NCT04165993, NCT04521179, NCT03847168, NCT04040699, NCT03619681) (Jiangsu Aphamab)	(5 studies)	187	1 & 2	Biparatropic HER2
MCLA-128/zenocutuzumab (Merus)	NCT03321981 NCT02912949	101 250	1 1/2	HER2 and HER3
ISB-1302 (Ichnos Sciences)	NCT03983395	158	1/2	HER2 and CD3
HER2Bi ATC (BiAb armed activated Tcells (Transtarget)	NCT03272334 NCT03661424	33 16	1 1	HER2 and CD3 HER2/CD3 in leptomeningeal dz
HER2Bi ATC (BiAb armed activated Tcells (Transtarget)	NCT01022138	32	2	HER2/CD3 (ER/PR+/HER2 Neg)
MBS301 (Beijing Mabworks)	NCT03842085	34	1	2 sites on HER2, afucosylated
M802 (Wuhan YZY)	NCT04501770	32	1	HER2 and CD3
BCD-147 (Biocad)	NCT03912441	15	1	2 sites on HER2
DF1001 (Dragonfly)	NCT04143711	220	1/2	HER2 and undisclosed NK engager
BTRC4017A (Merck)	NCT03448042	449	1/2	HER2 and CD3
IBI315 (Innovent)	NCT04162327	191	1a/1b	HER2 and PD-L1